US5770199A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for virus inactivation in the presence of polyalkylene glycol as well as the pharmaceutical preparation obtained therewith
Assignee: Oesterreichisches Institut fuer Haemoderivate
•
Filing: 1995-01-10
•
Granted: 1998-06-23
•
Expires: 2015-01-10
Abstract
Abstract PCT No. PCT/IB95/00019 Sec. 371 Date Jun. 28, 1996 Sec. 102(e) Date Jun. 28, 1996 PCT Filed Jan. 10, 1995 PCT Pub. No. WO95/09657 PCT Pub. Date Apr. 13, 1995The invention relates to a pharmaceutical preparation comprising a plasma protein wherein said preparation is free of infectious agents as well as essentially free of denaturation products and is obtainable by a method that encompasses the following steps: a) addition of a polyether and a chaotropic agent to a solution comprising the plasma protein, optional lyophilization of the solution; b) inactivation of infectious agents in the presence of the polyether by a physio-chemical or chemical treatment, and c) removal of the polyether and the chaotropic agent.
Inventors
- 👤 Johann Eibl
- 👤 Friedrich Dorner
- 👤 Noel Barrett
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 01:42
CPC Classifications
A; A61; A61L; A61L2/00; A61L2/16; A61L2/18; A61P; A61P31/00; A61P31/12; C; C07; C07K; C07K16/00; C07K16/06; A61L2103/00; A61L2103/05; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/829; Y10S530/83
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
65 words
A method for the production of a biological preparation, comprising (a) contacting a solution comprising a plasma protein with a polyether and a chaotropic agent to inactivate contaminating infectious agents by a physico-chemical or chemical treatment without the use of a detergent, and (b) removing the polyether and chaotropic agent to obtain the pharmaceutical preparation that is substantially free of infectious agents and denaturation products.
Claim 2
Independent Claim
65 words
A method for the production of a biological preparation, comprising (a) contacting a solution comprising a plasma protein with a polyether and a chaotropic agent to inactivate contaminating infectious agents by a physico-chemical or chemical treatment without the use of a detergent, and (b) removing the polyether and chaotropic agent to obtain the pharmaceutical preparation that is substantially free of infectious agents and denaturation products.
Claim 3
Dependent Claim
12 words
The method according to claim 1, wherein a polyhydroxyether is the polyether.
Claim 4
Dependent Claim
13 words
The method according to claim 2, wherein the polyhydroxyether is a polyalkylene glycol.
Claim 5
Dependent Claim
35 words
The method according to claim 3, wherein the polyalkylene glycol is a low molecular polyethylene glycol selected from the group consisting of PEG 200, PEG 300, PEG 400, PEG 600, PEG 900 and PEG 1000.
Claim 6
Dependent Claim
35 words
The method according to claim 1, wherein the inactivation of infectious agents is conducted in the presence of a polyether at a concentration of 5 to 30 percent by weight, wherein proteins are not precipitated.
Claim 7
Dependent Claim
22 words
The method according to claim 1, wherein the chaotropic agent is selected from the group consisting of thiocyanates, urea and guanidinium salts.
Claim 8
Dependent Claim
26 words
The method according to claim 6, wherein the chaotropic agent is a thiocyanate selected from the group consisting of ammonium thiocyanate, sodium thiocyanate and calcium thiocyanate.
Claim 9
Dependent Claim
13 words
The method according to claim 6, wherein the chaotropic agent is guanidinium hydrochloride.
Claim 10
Dependent Claim
19 words
The method according to claim 1, wherein the chaotropic agent is used at a concentration of 0.1 to 2M.
Claim 11
Independent Claim
60 words
A method for producing virally-inactivated preparation containing a plasma protein, comprising: (a) contacting the plasma protein with a polyether and a chaotropic agent to inactivate contaminating viruses without the use of a detergent, and (b) removing the polyether and chaotropic agent to obtain the virally-inactivated preparation, wherein the virally-inactivated preparation is substantially free of denatured forms of the plasma protein.
Claim 12
Independent Claim
60 words
A method for producing virally-inactivated preparation containing a plasma protein, comprising: (a) contacting the plasma protein with a polyether and a chaotropic agent to inactivate contaminating viruses without the use of a detergent, and (b) removing the polyether and chaotropic agent to obtain the virally-inactivated preparation, wherein the virally-inactivated preparation is substantially free of denatured forms of the plasma protein.
Claim 13
Dependent Claim
12 words
The method according to claim 10, wherein the polyether is a polyhydroxyether.
Claim 14
Dependent Claim
13 words
The method according to claim 11, wherein the polyhydroxyether is a polyalkylene glycol.
Claim 15
Dependent Claim
35 words
The method according to claim 12, wherein the polyalkylene glycol is a low molecular polyethylene glycol selected from the group consisting of PEG 200, PEG 300, PEG 400, PEG 600, PEG 900 and PEG 1000.
Claim 16
Dependent Claim
26 words
The method according to claim 10, wherein the polyether is at a concentration of 5 to 30 percent by weight, thereby avoiding the precipitation of proteins.
Claim 17
Dependent Claim
22 words
The method according to claim 10, wherein the chaotropic agent is selected from the group consisting of thiocyanates, urea and guanidinium salts.
Claim 18
Dependent Claim
26 words
The method according to claim 15, wherein the chaotropic agent is a thiocyanate selected from the group consisting of ammonium thiocyanate, sodium thiocyanate and calcium thiocyanate.
Claim 19
Dependent Claim
13 words
The method according to claim 15, wherein the chaotropic agent is guanidinium hydrochloride.
Claim 20
Dependent Claim
19 words
The method according to claim 10, wherein the chaotropic agent is used at a concentration of 0.1 to 2M.
Claim 21
Dependent Claim
13 words
The method according to claim 10, wherein the plasma protein is an immunoglobulin.
Claim 22
Dependent Claim
24 words
The method according to claim 10, wherein the plasma protein is selected from the group consisting of coagulation factors, fibrinolytic proteins and thrombolytic proteins.
Claim 23
Dependent Claim
32 words
The method according to claim 10, wherein the contacting occurs at a temperature of about 20° C. to about 60° C. over a period of about 1 hour to about 10 hours.
Claim 24
Dependent Claim
24 words
The method according to claim 10, wherein at least 80% of the activity level of the plasma protein is maintained in the virally-inactivated preparation.
Claim 25
Dependent Claim
24 words
The method according to claim 22, wherein at least 90% of the activity level of the plasma protein is maintained in the virally-inactivated preparation.
References Cited (Backward Citations)
US2232820A
Cited
US2303432A
Cited
US2232821A
Cited
US2380166A
Cited
US4069216A
Cited
FR2339621A1
Cited
US4315919A
Cited
EP0050061A2
Cited
EP0083999A1
Cited
EP0099445A2
Cited
US4481189A
Cited
US5055557A
Cited
EP0124506A2
Cited
US4727027A
Cited
US4764369A
Cited
EP0177836A2
Cited
US4721777A
Cited
US5132406A
Cited
EP0292003A2
Cited
WO1990007524A1
Cited
EP0399321A2
Cited
WO1990015613A1
Cited
EP0479597A2
Cited
EP0530173A2
Cited
DE4434538A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-06-22 | 2001-12-22 | 2002-06-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-06-22 | 2005-12-22 | 2006-06-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-06-22 | 2009-12-22 | 2010-06-23 | $7700.00 | Window Closed / Lapsed |